Although, several tyrosine kinase inhibitors targeting the BCR-ABL hybrid have been developed and shown to be successful for chronic myeloid leukemia treatment, leukemia cells can become resistant to treatment [5]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.